Recent Head and Neck Cancer News

Head and Neck Cancer Patients at Risk of Cognitive Problems Following Treatment (January 8, 2018)

CancerConnect News: Patients who survive head and neck cancer may be more likely to experience declines in mental function according to the results of a recent study. The findings are drawn from cognitive... Continue Reading

U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial (August 21, 2017)

CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study... Continue Reading

Head and Neck Cancer-What You Need to Know (August 14, 2017)

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most... Continue Reading

Targeted radiotherapy for head and neck cancer could reduce the risk of dry mouth (February 22, 2017)

A troublesome side effect of radiation therapy treatment of cancers involving the head and neck is dry mouth.  This occurs as a consequence of radiation damage to the salivary glands.  According to a... Continue Reading

Nearly half of U.S. men actively infected with HPV, study finds HPV-linked cancers on the rise in men, but nearly 9 in 10 vaccine-eligible men are unvaccinated! (February 20, 2017)

By Rachel Tompa / Fred Hutch News Service The most common sexually transmitted infection in the U.S. has a bit of a twist. It’s what’s known as a “subclinical infection” — those infected suffer... Continue Reading

Twice-daily radiation therapy reduces mortality from head and neck cancer (February 14, 2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress... Continue Reading

Opdivo Approved for Advanced Head and Neck Cancer (November 28, 2016)

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is... Continue Reading

PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment (October 5, 2016)

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment... Continue Reading

Keytruda® Approved for Advanced Head and Neck Cancer (September 7, 2016)

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy... Continue Reading

Compliance with Radiation Schedules Improves Survival in Head and Neck Cancer (June 9, 2016)

Patients with head and neck cancer who comply with their scheduled radiation treatments have significantly improved outcomes compared to those who miss 2 or more of their appointments within the prescribed... Continue Reading

Next Page »